Uroxatral Related Published Studies
Well-designed clinical trials related to Uroxatral (Alfuzosin)
Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. [2008.06]
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. [2007.01.09]
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. [2007]
Alfuzosin (10 mg) does not affect blood pressure in young healthy men. [2006.12]
Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. [2006.10]
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. [2006.06]
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. [2006.04]
Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). [2006.03]
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. [2006]
Three months' treatment with the alpha(1)-blocker alfuzosin does not affect total or transition zone volume of the prostate. [2005.11.22]
A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. [2005.09]
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. [2005.05]
The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. [2005.03]
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. [2005.01]
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. [2004.06]
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. [2004.04]
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. [2003.11]
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. [2003.09]
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. [2003.08]
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. [2002.10]
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. [2002.07]
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. [2001.12]
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group] [2000.04]
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. [2000.03]
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. [1999.10]
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. [1998.09]
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. [1997.10]
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. [1997.06]
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. [1997]
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. [1997]
Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. [1995.01]
Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. [1994.12]
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. [1994.11]
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. [1994]
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. [1993.12]
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. [1993.11]
Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses. [1992.11]
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group. [1992.07]
Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. [1992]
Comparison of the new alpha 1-blocker alfuzosin with propranolol as first-line therapy in hypertension. [1991.07]
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. [1991.06.15]
Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate. [1991]
Alfuzosin and the venous reflex response: studies in normal subjects. [1989.01]
Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. [1989]
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study] [1988]
Well-designed clinical trials possibly related to Uroxatral (Alfuzosin)
Role of alpha1-blockers in chronic prostatitis syndromes. [2008.03]
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. [2005.12]
Clinical assessment of drug-induced QT prolongation in association with heart rate changes. [2005.04]
Prostate size influences the outcome after presenting with acute urinary retention. [2004.09]
The efficacy and safety of a new once-a-day formulation of an alpha-blocker. [2001.03]
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. [1999.10]
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. [1998.07]
Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. [1997.09]
Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. [1996.10]
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group. [1996.04]
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. [1995.10]
Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. [1995]
Other research related to Uroxatral (Alfuzosin)
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. [2008.04]
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. [2008.04]
Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. [2008.02.04]
Alfuzosin delays cardiac repolarization by a novel mechanism. [2008.02]
Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. [2007.09]
Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. [2007.07]
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. [2007.06]
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. [2007.01.16]
Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats. [2006.10]
Stuttering priapism after ingestion of alfuzosin. [2006.10]
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. [2006.09]
Alfuzosin (10mg) Does Not Affect Blood Pressure in Young Healthy Men. [2006.06.28]
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. [2006.06]
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. [2006.04]
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. [2006.03]
Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia. [2006.03]
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. [2006.02]
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. [2006.01]
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. [2005.10]
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. [2005.09]
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. [2005.08]
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. [2005.08]
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. [2005.03]
Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*. [2005]
Alfuzosin-induced acute hepatitis in a patient with chronic liver disease. [2004.09]
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. [2004.03]
Alfuzosin for the management of benign prostate hyperplasia. [2003.11]
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. [2003.07.15]
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. [2003.07]
Clinical and pressure-flow changes after long-term treatment with alfuzosin SR. [2003]
Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment. [2002.12]
Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. [2002.11]
Alfuzosin: a clinically uroselective alpha1-blocker. [2002.04]
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. [2002.01]
Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. [2002]
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. [2001.03]
The efficacy of alfuzosin treatment in patients with prostatism. [2001]
The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. [2000.09]
Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. [2000.04]
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. [2000.04]
[Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin] [2000.02]
Alfuzosin-induced hepatotoxicity. [2000.02]
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. [2000.02]
[Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice] [1999.04]
|
